Eli Lilly and Company $LLY is South Street Advisors LLC's 6th Largest Position

Key Points

• South Street Advisors LLC trimmed its Eli Lilly stake by 4.3% in the fourth quarter, but LLY still remains its 6th-largest position and about 4.3% of the portfolio.
• Eli Lilly reported strong quarterly results, with EPS of $8.55 beating estimates and revenue of $19.8 billion topping forecasts, while sales rose 55.5% year over year.
• The company continues to draw positive attention from investors and analysts, with bullish price-target increases, expanded coverage for its obesity drugs, and a quarterly dividend of $1.73 per share.

South Street Advisors LLC cut its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 4.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 28,426 shares of the company's stock after selling 1,264 shares during the period. Eli Lilly and Company comprises approximately 4.3% of South Street Advisors LLC's portfolio, making the stock its 6th largest position. South Street Advisors LLC's holdings in Eli Lilly and Company were worth $30,549,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. 10Elms LLP lifted its position in Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company's stock valued at $31,000 after acquiring an additional 10 shares during the last quarter. M.E. Allison & CO. Inc. increased its position in Eli Lilly and Company by 0.7% in the 4th quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company's stock valued at $1,587,000 after acquiring an additional 10 shares during the period. Tanager Wealth Management LLP increased its position in Eli Lilly and Company by 2.6% in the 4th quarter. Tanager Wealth Management LLP now owns 395 shares of the company's stock valued at $424,000 after acquiring an additional 10 shares during the period. Morey & Quinn Wealth Partners LLC increased its position in Eli Lilly and Company by 1.5% in the 4th quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company's stock valued at $710,000 after acquiring an additional 10 shares during the period. Finally, Wealthspan Partners LLC increased its position in Eli Lilly and Company by 0.5% in the 4th quarter. Wealthspan Partners LLC now owns 2,110 shares of the company's stock valued at $2,268,000 after acquiring an additional 10 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Up 4.0%

NYSE LLY opened at $1,126.66 on Friday. The stock has a market capitalization of $1.06 trillion, a P/E ratio of 40.02, a P/E/G ratio of 1.18 and a beta of 0.48. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,149.10. The firm has a 50-day moving average price of $952.15 and a 200 day moving average price of $1,009.10. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to analysts' expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm's revenue for the quarter was up 55.5% on a year-over-year basis. During the same period in the prior year, the company posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts expect that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company's dividend payout ratio is currently 24.58%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark is restoring coverage for Zepbound and adding Foundayo to drug plans, and Lilly said all three of the largest U.S. pharmacy benefit managers now cover its full obesity portfolio, improving commercial access and revenue potential. Reuters: CVS brings back coverage for Lilly's obesity drug Zepbound
• Positive Sentiment: Lilly announced three vaccine acquisitions worth up to about $3.8 billion, signaling a broader growth strategy beyond obesity and diabetes and potentially opening a new long-term market opportunity. Reuters coverage of Lilly vaccine acquisitions
• Positive Sentiment: New clinical data presented for Foundayo, Mounjaro, and retatrutide highlighted strong efficacy in obesity and diabetes, reinforcing investor confidence in Lilly’s cardiometabolic pipeline. PR Newswire: Lilly to present new data...
• Positive Sentiment: Several analysts reiterated bullish views and higher price targets, including a BofA target increase, which supports the stock’s momentum and valuation narrative. InsiderMonkey: Eli Lilly among safe stocks
• Neutral Sentiment: Lilly’s presentation at Bernstein and upcoming conference appearances are keeping investors focused on management commentary, but these events are more about confirming the existing growth story than creating a new catalyst. Seeking Alpha transcript
• Negative Sentiment: Some commentary argues Novo Nordisk may be a better short-term value, and Lilly’s rich valuation could limit upside if growth expectations slow. Motley Fool: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on LLY. Wells Fargo & Company boosted their price target on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an "overweight" rating in a research report on Thursday, February 5th. Barclays boosted their price target on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an "overweight" rating in a research report on Monday, May 4th. Sanford C. Bernstein restated an "outperform" rating on shares of Eli Lilly and Company in a research report on Tuesday, March 10th. Freedom Capital upgraded Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, February 10th. Finally, Berenberg Bank boosted their price target on Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a "hold" rating in a research report on Thursday, February 19th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and a consensus target price of $1,227.00.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.